Market Drivers and Restraints
The rise in the number of patients with urinary urgency and high frequency, and nocturia; typically diagnosed with overactive bladder (OAB) can boost the need for effective treatment. The rise in occurrences of neurological diseases, especially among the growing geriatric group, can prompt the need for OAB management that can support the expansion of the global OAB market in the assessment period. In addition, upgradation and innovations of intravesical therapies and rapid commercialization of such new launches by pharma companies can prompt the market rise in the assessment tenure.
Market Research Future (MRFR) studied the global overactive bladder treatment market 2021 in the review period till 2023. As per MRFR daat, the overactive bladder treatment market is expected to thrive at 3.1% CAGR during the forecast tenure (from 2018 to 2023). By 2023, the global overactive bladder treatment market is expected to earn decent value.
The market of overactive bladder treatment is assessed across the Americas, Asia Pacific, Europe, and the Middle East and Africa. In North America, the overactive bladder treatment is expected to thrive at a considerable pace owing to expansion of geriatric populace and rise in incidences of urinary and OAB incontinence symptoms. In addition, the introduction of healthcare coverage systems, such as; Medicare can add to the rise of the market in the Americas.
According to the data by National Association for Continence (NAFC), around 25 million Americans adults experience chronic urinary incontinence and transients. The range is around 75 to 80% for women suffering from overactive bladder. In Europe, the market of overactive bladder looks lucrative. The rise in occurrences of OAB and hike in healthcare expenditure are causes that are likely to prompt the market in the assessment period. In Asia Pacific, the availability of affordable reimbursement options can aid the regional OAB market to surge.
The increase in cases of OAB among geriatric population, along with rise in cognizance of its modern treatment can prompt APAC market in the review tenure. The existence of robust medical setup and launch of initiatives taken by APAC governments to support medical attention for the middle class population can favor the regional OAB market. In the Middle East region and Africa, the overactive bladder treatment market can witness sluggish growth owing to socio-political backwardness.
Astellas Pharma Inc., Pfizer, Inc., Allergan, Plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Endo International Plc, Sanofi S. A., Aurobindo Pharma Limited, Intas Pharmaceuticals Ltd., Johnson & Johnson, Apotex Inc., Medtronic PLC, Macleods Pharmaceuticals Ltd., and Cogentix Medical, Inc., are some top-notch companies that are operating in the overactive bladder treatment market as listed by MRFR.